Market Outlook

Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and GEJ adenocarcinoma in the major pharmaceutical markets under study, and neither agent is approved to treat esophageal cancer. Roche/Genentech/Chugai’s Herceptin is the first-line standard of care for HER2-positive metastatic patients, and Eli Lilly’s Cyramza is approved for patients with advanced disease following fluoropyrimidine- and platinum-based therapy. Additionally, two PD-1 inhibitors—Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo (Japan only) and Merck & Co.’s Keytruda (United States only)—are approved to treat third- and later-line gastric and GEJadenocarcinoma. Despite these approvals, the gastroesophageal cancer therapy market is largely untapped and thus represents a lucrative opportunity for drug developers. The late-phase pipeline is buoyant; agents span a range of drug classes and target various gastroesophageal cancer populations associated with significant unmet need. These treatments may soon offer patients a more-optimistic outlook.

Questions Answered

  • How do current treatment practices differ between esophageal, gastric, and GEJcancer, and which populations provide the greatest drug-treatment opportunities by geography?
  • What are interviewed thought leaders’ insights on Herceptin, Cyramza, Keytruda, Opdivo, and chemotherapy? What clinical needs remain unfulfilled, and on which opportunities can developers capitalize?
  • Which other immune checkpoint inhibitors (Bavencio, Yervoy, tislelizumab) are expected to be approved and in which disease setting(s), and how will they compete with currently marketed and established therapies?
  • What agents with novel mechanisms of action are being assessed in Phase III trials, which populations are they targeting, and how will they impact the gastroesophageal cancer therapy market?
  • What are the market drivers and constraints in the gastroesophageal market, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Related Reports

Gastroesophageal Cancer - Landscape & Forecast - Disease Landscape & Forecast

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma&mdas...

View Details

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma and Esophageal Cancer | Disease Landscape & Forecast | G7 | 2020

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—continues to rise; however, treatment options remain limi...

View Details

Gastroesophageal Cancer - Geographic Focus: China - Gastric Cancer - China In-Depth (China)

China has the highest incidence of gastric and GEJ adenocarcinoma globally, and therapeutic options are limited. Only three targeted agents are approved to treat this indication—Roche’s...

View Details

Gastroesophageal Cancer - Unmet Need - Detailed, Expanded Analysis (US & EU) Previously Treated Metastatic Gastric And Gastroesophageal Junction (GEJ) Adenocarcinoma

While the incidence of gastric and GEJ adenocarcinoma continues to rise, efficacious treatment options, especially in the previously treated metastati...

View Details